Observational studyJournal of gastroenterology2020
Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society.
Observational study in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Implications and risk of new versus persisting intraductal papillary mucinous neoplasms after pancreatic surgery: meta-analysis.BJS open · 2026Pooled it
- Long-Term Oncologic Outcome following Duodenum-Preserving Pancreatic Head Resection for Benign Tumors, Cystic Neoplasms, and Neuroendocrine Tumors: Systematic Review and Meta-analysis.Annals of surgical oncology · 2024Pooled it
- Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta-Analysis.World journal of surgery · 2022Pooled it
- Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026Article
- Decision Modeling to Guide Management of Pancreatic IPMNs: Immediate Surgery or Initial Surveillance?Annals of surgical oncology · 2026Article
- Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: History, Myths, and Realities Between Past and Future.Medical sciences (Basel, Switzerland) · 2026Review
- Evaluating the Kyoto Guidelines' Worrisome Features and High-Risk Stigmata to Predict High-Grade Dysplasia and Invasive Cancer in Intraductal Papillary Mucinous Neoplasms.Annals of surgical oncology · 2026Article
- Investigation of the Optimal Duration and Modality for Postoperative Surveillance of Intraductal Papillary Mucinous Neoplasm (IPMN): A Single-Center Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Intraductal papillary mucinous neoplasm with pseudomyxoma peritonei: a case report.International journal of surgery case reports · 2026Article
- High-grade and Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas with STK11 Aberration Having Undergone Pancreatic Resection Three Times for Metachronous Intrapancreatic Recurrences: A Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2025Review
- Important radiological and clinicopathological risk factors for the recurrence of intraductal papillary mucinous neoplasms after surgical resection.European radiology · 2025Article
- Middle segment preserving pancreatectomy versus total pancreatectomy: a comparative analysis of short- and long-term outcomes.Surgery today · 2025Article
- Essential Update 2023/2024: Multidisciplinary Treatment for Invasive Intraductal Papillary Mucinous Carcinoma.Annals of gastroenterological surgery · 2025Review
- Assessing Follow-Up Duration in Intraductal Papillary Mucinous Neoplasm Patients.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Clinical impact of epithelial types on postoperative outcomes for intraductal papillary mucinous neoplasms: a multicenter retrospective study.Journal of gastroenterology · 2025Observational
- An Overview for Clinicians on Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas.Cancers · 2024Review
- A Review of the Indications, Outcomes, and Postoperative Management After Total and Completion Pancreatectomy for Pancreatic Cancer: More Is Not Necessarily Better.The Surgical clinics of North America · 2024Review
- Is multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma?Annals of gastroenterological surgery · 2024Article
- Repeated Minimally Invasive Pancreatectomy for Intraductal Papillary Mucinous Neoplasm in the Remnant Pancreas: A Case Report.The American journal of case reports · 2024Article
- Rare tumours of the pancreas: monocentric study.Journal of cancer research and clinical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 1 country.
Funding
Abstract
backgroundAlthough there are numerous reports focusing on surgical indication for intraductal papillary mucinous neoplasm (IPMN), the recurrence patterns following surgery are less widely reported. To ascertain optimal treatment and postoperative surveillance for IPMN patients, we analyzed patterns and risk factors for recurrence after surgery for IPMN.
methodsThis study is a retrospective, multi-institutional, observational study, including 1074 patients undergoing surgery for IPMN at 11 academic institutions. We analyzed the risk factors for recurrence after classifying postoperative recurrences into metachronous high-risk lesions (malignant progression of IPMN and/or metachronous pancreatic ductal adenocarcinoma) in the remnant pancreas and extra-pancreatic recurrence.
resultsOf 1074 patients undergoing surgery for IPMN, 155 patients (14.4%) developed postoperative recurrence. We found that 34.3% of 70 high-risk lesions in the remnant pancreas occurred over 5 years after surgery, and survival of 36 patients undergoing second operation for high-risk lesions was better than that of 34 patients who did not (P = 0.04). We found four independent risk factors for metachronous high-risk lesions in remnant pancreas: symptoms [P = 0.005, hazard ratio (HR) 1.988], location of pancreatic body/tail (P < 0.001, HR 3.876), main duct size ≥ 10 mm (P = 0.021, HR 1.900), and high-grade dysplasia/invasive intraductal papillary mucinous carcinoma (IPMC) (P < 0.001, HR 3.204). Although six patients (0.7%) with low- or high-grade dysplasia IPMN developed extra-pancreatic recurrence, invasive IPMC was the strongest risk factor for extra-pancreatic recurrence (P < 0.001, HR 39.667).
conclusionWe suggest that life-time continuous surveillance might be necessary for IPMN patients. Second surgery for metachronous high-risk lesions in remnant pancreas should be considered to improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.